Researchers from the University of Kent's School of Biosciences have provided evidence that a newly discovered Ebolavirus may not be as deadly as other species to humans.
The new Bombali virus was discovered in bats in Sierra Leone and has also now been reported in bats in Kenya. To date, it was unclear whether the Bombali virus may be pathogenic to humans.
Dr. Mark Wass and professor Martin Michaelis developed a computational approach to compare the amino acid sequences of virus proteins to identify positions that determine whether a virus causes disease in humans. Their findings showed that certain positions in the VP24 protein of the Bombali virus are identical to the Reston virus, another member of the Ebolavirus family that is not pathogenic in humans. This is consistent with the origin of the Bombali virus, which was isolated from fruit bats that were cohabitating with humans in houses and other populated areas. Although this makes human contact highly likely, no disease outbreaks have been reported
Wass said, "Based on our findings, it does not seem likely that the Bombali virus causes severe disease in humans. However, we need to be careful as we know that a few mutations may change this and result in another Ebolavirus that poses a threat to humans. Hence, Bombali virus evolution should be carefully monitored."
The study, "Is the Bombali virus pathogenic in humans?" by Henry Martell, Stuart Masterson, Jake McGreig, Martin Michaelis, Mark Wass, was published in the journal Bioinformatics. See: 10.1093/bioinformatics/btz267
Source: University of Kent
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.